Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
On Wednesday, Citizens JMP has maintained a positive outlook on BioCryst Pharmaceuticals (NASDAQ:BCRX), currently trading at $7.82, reiterating a Market Outperform rating alongside an $18.00 price target. According to InvestingPro data, analyst targets range from $8 to $30, with the stock showing impressive revenue growth of 36% over the last twelve months. The firm’s analyst, Jonathan Wolleben, highlighted the consistent growth in sales of Orladeyo, a treatment developed by BioCryst, which is anticipated to reach approximately $800 million in U.S. revenue by the year 2029. The company’s management has projected sales in 2025 to fall between $535 million and $550 million, a target that Citizens believes is within reach, estimating $542 million based on the strong launch fundamentals observed. InvestingPro analysis shows the company maintains a healthy current ratio of 2.63, indicating strong short-term financial stability, though investors should note the stock’s high volatility with a beta of 1.75.
BioCryst’s development pipeline shows promise with the anticipated release of the first clinical data for BCX17725, a treatment for Netherton syndrome, and avoralstat, which is being tested for delivery in Diabetic Macular Edema (DME) by year-end. The analyst expressed optimism for both programs, noting BCX17725’s potent efficacy, which is ten times higher than the natural inhibitor, and its favorable pharmacokinetic profile that may allow for subcutaneous dosing every two weeks or longer.
The company’s work on avoralstat also received a positive nod, with recent mid-stage data suggesting that plasma kallikrein inhibitors could reduce central subfield thickness in DME patients, thereby supporting the mechanism of action behind avoralstat. The firm anticipates that delivering the drug suprachoroidally will be the most effective method to maximize its benefits for DME treatment. These upcoming programs are considered potential upsides to BioCryst’s valuation, and Citizens JMP’s outlook reflects confidence in the company’s future performance.
In other recent news, BioCryst Pharmaceuticals Inc. reported notable changes in its executive team, including the resignation of Chief Financial Officer Anthony Doyle, effective April 9, 2025. The company has appointed CEO Jon P. Stonehouse as the Interim CFO while it searches for a new financial leader. In parallel, BioCryst has taken legal action to protect its ORLADEYO patents, filing a lawsuit against Annora Pharma to prevent generic competition. The lawsuit, filed in the United States District Court for the District of Delaware, challenges Annora’s ANDA filing, asserting infringement on patents expiring in 2039.
Analysts have also weighed in on BioCryst’s prospects, with JMP Securities maintaining a Market Outperform rating, citing positive results from the APeX-P trial for Orladeyo in pediatric patients. Meanwhile, H.C. Wainwright reiterated a Buy rating with a $30 price target, highlighting optimism for BCX17725, a potential treatment for Netherton syndrome. This therapy aims to address a significant unmet need in the rare disease market. These developments come as BioCryst continues to focus on its pipeline and market opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.